EP1810689A1 - Mittel zur prävention und/oder behandlung von diabetes - Google Patents

Mittel zur prävention und/oder behandlung von diabetes Download PDF

Info

Publication number
EP1810689A1
EP1810689A1 EP05793213A EP05793213A EP1810689A1 EP 1810689 A1 EP1810689 A1 EP 1810689A1 EP 05793213 A EP05793213 A EP 05793213A EP 05793213 A EP05793213 A EP 05793213A EP 1810689 A1 EP1810689 A1 EP 1810689A1
Authority
EP
European Patent Office
Prior art keywords
prophylactic
agent
therapeutic treatment
diabetes
colestimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05793213A
Other languages
English (en)
French (fr)
Other versions
EP1810689A4 (de
Inventor
Kazuo c/o Zoegene Corporation SUZUKI
Kaoru c/o Mitsubishi Pharma Corporation SAKAI
Shinichi c/o Mitsubishi Pharma Corporation ISHII
Kanami Mitsubishi Pharma Corporation SUGIMOTO
Johan c/o University Louis Pasteur IGBMC AUWERX
Mitsuhiro c/o University Louis Pasteur WATANABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of EP1810689A1 publication Critical patent/EP1810689A1/de
Publication of EP1810689A4 publication Critical patent/EP1810689A4/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel agent for prophylactic and/or therapeutic treatment of diabetes.
  • Farnesoid X receptor is a nuclear receptor that binds to bile acid as a ligand, and is known to negatively regulate gene expression of cholesterol 7 ⁇ hydroxylase (cyp7 a) which is a rate limiting enzyme of conversion of cholesterol into bile acid (Non-patent document 1).
  • cyp7 a cholesterol 7 ⁇ hydroxylase
  • SHP small heterodimer partner
  • Medicaments that change the FXR activity are considered to be effective for diseases associated with abnormally high or low cholesterol levels.
  • Anion exchange resins known as hypocholesterolemic agents, inhibit the FXR activity by adsorbing bile acid which is an endogenous ligand of FXR, and thereby increase the expression of cyp7 ⁇ (Non-patent document 4). As a result, synthesis of bile acid from cholesterol is promoted, and thus these medicaments have been proved to be useful as hypocholesterolemic agents.
  • FXR is also known to form a heterodimer with retinoic acid receptor (RXR) as a nuclear receptor.
  • RXR retinoic acid receptor
  • the RXR is known to interact with nuclear receptors such as peroxisome proliferator-activated receptor (PPAR) ⁇ and PPAR ⁇ , and it has been suggested that changes in the FXR activity may act on various diseases such as obesity, diabetes and abnormal lipid metabolism in which PPAR ⁇ , PPAR ⁇ , or the like is involved (Patent document 1).
  • PPAR peroxisome proliferator-activated receptor
  • PPAR ⁇ peroxisome proliferator-activated receptor
  • PPAR ⁇ peroxisome proliferator-activated receptor
  • PPAR ⁇ peroxisome proliferator-activated receptor
  • liver gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) are inhibited via SHP by the activation of FXR (Non-patent document 5, Patent document 2).
  • liver gluconeogenesis is conversely inhibited by inhibition of the FXR activity.
  • colestimide which is an anion exchange resin known as a hypocholesterolemic agent (trade name: Cholebine, Mitsubishi Pharma Corporation)
  • reports have so far made on hypoglycemic action after administration over a certain period of time (Non-patent document 6) and an effect on the circadian variation of blood glucose levels in hypercholesterolemia patients also suffering from type 2 diabetes (Patent document 4).
  • Patent document 6 Non-patent document 6
  • Patent document 4 an effect on the circadian variation of blood glucose levels in hypercholesterolemia patients also suffering from type 2 diabetes
  • An object of the present invention is to provide a novel agent for prophylactic and/or therapeutic treatment of diabetes.
  • the inventors of the present invention conducted various researches to achieve the foregoing object. As a result, they found that a substance inhibiting the activity of the farnesoid X receptor was effective for prophylactic and/or therapeutic treatment of diabetes, and accomplished the present invention.
  • the gists of the present invention are as follows:
  • an agent for prophylactic and/or therapeutic treatment of diabetes containing a substance inhibiting the activity of the farnesoid X receptor as an active ingredient can be provided.
  • the farnesoid X receptor is a nuclear receptor binding to bile acid as a ligand, which positively regulates the gene expression of the inhibitory nuclear receptor, small heterodimer partner (SHP), and negatively regulates the gene expression of cholesterol 7 ⁇ hydroxylase (cyp7 a) that is a rate limiting enzyme in conversion of cholesterol into bile acid ( Science, 284(5418):1362-5, 1999 ).
  • the FXR activity can be determined on the basis of a gene expression level of cyp7 ⁇ or SHP.
  • the expression levels of genes for cyp7 ⁇ and SHP can be determined by real time quantitative PCR (TaqMan Universal PCR Master Mix (Applied Biosystems)), or the like.
  • a substance that inhibits the activity of the farnesoid X receptor means a substance that increases the expression level of the gene for cyp7 ⁇ about 2- to 15-fold and/or a substance that decreases the expression level of the gene for SHP by about 20 to 70%.
  • Preferred examples include a substance that increases the expression level of the gene for cyp7 ⁇ about 4- to 10-fold and/or a substance that decreases the expression level of the gene for SHP by about 30 to 60%
  • more preferred examples include a substance that increases the expression level of the gene for cyp7 ⁇ about 8-fold and/or a substance that decreases the expression level of the gene for SHP by about 50%.
  • inhibition of liver gluconeogenesis means decreases in the expression levels of genes for liver gluconeogenic enzymes such as each of glucose-6-phosphatase (G6Pase) and/or phosphoenolpyruvate carboxykinase(PEPCK) by about 20 to 70%, preferably about 30 to 70%, most preferably about 40%.
  • the expression levels of genes for G6Pase, PEPCK and the like can be determined by the aforementioned real time quantitative PCR or the like.
  • the expression “increase in energy metabolism” means increases in basal metabolism and heat production, and the “basal metabolism” means oxygen consumption per body surface area or per unit body weight.
  • the expression "basal metabolism increases” means that oxygen consumption per unit body weight increased by about 5%, preferably about 10 to 15%.
  • the expression "heat production increases” means that expressions of each of genes encoding heat production-related proteins existing in brown adipose tissue (BAT) increases 1.3- to 2-fold, preferably about 3- to 4-fold.
  • BAT brown adipose tissue
  • Examples of the heat production-related proteins in the BAT of small animals include deiodinase 2 (Dio2), uncoupler protein 1 (UCP-1), PPAR gamma coactivator 1a (PGC-1a), and the like.
  • Dio2 is an enzyme that converts thyroxine (T4), a thyroid hormone, into triiodothyronine (T3).
  • T3 A primary action of T3 is to increase metabolism (increases in basal metabolism level and heat production).
  • UCP-1 plays a role of causing uncoupling ofADP-induced oxidative phosphorylation, that is, directly converting energy, that is generated by catabolism, to heat without converting it into a high-energy phosphate compound such as ATP.
  • PGC-la is a coactivator of nuclear transcription factors and positively regulates expressions of the genes for UCP-1 and Dio2.
  • a pharmaceutically acceptable anion exchange resin means an anion exchange resin that can be administered as a medicament, and preferred examples include anion exchange resins having a bile acid-adsorbing ability. As shown in the following examples, the anion exchange resins are not particularly limited so long as they inhibit liver gluconeogenesis and increase energy metabolism when they are administered .
  • colestimide (2-methylimidazole-epichlorohydrin copolymers) which is the most preferred example.
  • the resin is represented by the basic structure of the following formula (I), of which structure is partially represented by the following formula (II), and can be obtained by a polymerization reaction of an epichlorohydrin derivative and an amine of which typical example is an imidazole derivatives, specifically, by the preparation method described in Japanese Patent Unexamined Publication (Kokai) No. 60-209523 .
  • Colestimide is registered with a nonproprietary name of colestimide (chemical name: 2-methylimidazole-epichlorohydrin copolymer) in JAN.
  • the resin is registered with a nonproprietary name of colestilan (chemical name: 2-methylimidazole polymer with 1-chloro-2,3-epoxypropane) in INN.
  • anion exchange resin examples include the aforementioned cholestyramine resin, colestipol (N-(2-aminoethyl-N'-[2-[(2-amino-ethyl)amino]ethyl]-1,2-ethanediamine polymer added with (chloromethyl)oxylane) and the like. These resins are sold by Sigma.
  • the cholestyramine resin is a strong basic anion exchange resin containing a styrene-divinylbenzene copolymer added with quaternary ammonium groups, and the basic structure thereof is represented by the following formula (III).
  • sevelamer hydrochloride is represented by the following formula, and said resin can be prepared by the method described in U.S. Patent No. 5,496,545 or similar methods.
  • the basic structure of colesevelam hydrochloride is represented by the following formula.
  • the resin can be prepared by the method described in U.S. Patent No. 5,607,669 or similar methods.
  • anion exchange resins described in International Patent Unexamined Publication in Japanese (Kohyo) Nos. 9-504782 , 9-500368 , 10-501264 , 10-501842 , 11-507093 , 11-512074 , and 5-512332 and Japanese Patent Unexamined Publication (Kokai) Nos. 8-208750 , 9-202732 , 10-114661 , and 11-228449 can also be used in the present invention so long as they do not depart from the gist of the present invention.
  • the farnesoid X receptor antagonist is not particularly limited so long that it inhibits liver gluconeogenesis and increases energy metabolism when administered, and may be a low molecular compound.
  • the endogenous ligands of FXR, transporters known to be involved in reabsorption of bile acid from the intestinal tract to the liver (enterohepatic circulation) and substances that inhibit bile acid-binding proteins are considered to be encompassed in the scope of the agent for prophylactic and/or therapeutic treatment of diabetes of the present invention.
  • transporters include ileal apical sodium co-dependent bile acid transporter/ileal bile acid transporter (ASBT/IBAT), Na+/taurocholate cotransporting polypeptide (NTCP), and the like
  • NTCP Na+/taurocholate cotransporting polypeptide
  • bile acid-binding proteins include ileal bile acid binding protein (IBABP), and the like.
  • the aforementioned compounds as an active ingredient per se may be used as the agent for prophylactic and/or therapeutic treatment of diabetes of the present invention.
  • Pharmaceutical compositions containing the aforementioned active ingredients and commonly used additives for pharmaceutical preparations are preferably prepared and used.
  • compositions examples include tablets, capsules, subtilized granules, pills, troches, solutions and the like, and these are orally administered (including sublingual administration).
  • Oral pharmaceutical compositions can be prepared by conventional methods such as mixing, filling and compressing. Further, the active ingredient may be distributed in a pharmaceutical composition by using a large amount of excipient and by applying repeated mixing operations.
  • tablets or capsules used for oral administration are preferably provided as unit administration products and may contain carriers ordinarily used for pharmaceutical preparations such as binders, fillers, diluents, compressing agents, lubricants, disintegrating agents, coloring materials, flavors, and wetting agents. Tablets may be prepared as, for example, coated tablets by using a coating agent according to methods known to those skilled in the art.
  • excipients include cellulose, mannitol, lactose and the like.
  • Starch, polyvinylpyrrolidone, starch derivatives such as sodium starch glycolate and the like as disintegrating agents, sodium laurylsulfate as lubricant, and the like can be used as additives for pharmaceutical preparations.
  • pharmaceutical compositions in the form of oral liquid include pharmaceutical compositions such as aqueous or oily suspensions, solutions, emulsions, syrups and elixirs and dry pharmaceutical compositions that can be redissolved in water or a suitable medium before use.
  • suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and hydrogenated edible fat; emulsifiers such as lecithin, sorbitan monooleate and gum arabic; oily esters such as almond oil, rectified coconut oil and glycerin esters; non-aqueous media such as propylene glycol and ethyl alcohol (edible oil may be included); preservatives such as methyl ester, ethyl ester or propyl ester of p-hydroxybenzoic acid and sorbic acid; usual flavors or coloring materials and the like, if necessary.
  • suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and hydrogenated edible fat
  • emulsifiers such as lecithin, sorbitan monooleate and gum arabic
  • oily esters such
  • the aforementioned oral pharmaceutical composition is in the form of, for example, a tablet, capsule, subtilized granule or the like, the composition usually contains 5 to 95% by weight, preferably 25 to 90% by weight, of the active ingredient.
  • Colestimide is sold by Mitsubishi Pharma Corporation with a trade name of Cholebine. Cholebine, per se, may be used according to the present invention.
  • a dose of the agent for prophylactic and/or therapeutic treatment of diabetes of the present invention can be suitably selected depending on the active ingredient to be used, the age, health condition and body weight of a patient, severity of diseases, type and frequency of treatment simultaneously applied, nature of desired effect, and the like.
  • a daily dose of 1 to 60 g for an adult in terms of the amount of the active ingredient can be administered once or several times per day.
  • the control group was fed with normal diet
  • the colestimide group was fed with normal diet containing 2% colestimide (UAR, Villemoison sur Orge, France).
  • oral glucose tolerance test was performed according to an ordinary method. Blood was collected before glucose load, a glucose solution was orally administered at a dose of 2 g/kg body weight, and blood sugar levels were measured 30, 60, 90, 120 minutes later.
  • livers were isolated from mice, and expression levels (relative mRNA levels) of the genes for the bile acid synthetase, cyp 7 a, the inhibitory nuclear receptor, SHP, and the gluconeogenic enzymes, PEPCK and G6Pase, were measured by real time quantitative PCR.
  • primer sequences used for the real time quantitative PCR those of SEQ ID NOS: 1 and 2 in the sequence listing were used for Cyp7 ⁇ , those of SEQ ID NOS: 3 and 4 in the sequence listing for SHP, those of SEQ ID NOS: 5 and 6 in the sequence listing for PEPCK, and those of SEQ ID NOS: 7 and 8 in the sequence listing for G6Pase, respectively.
  • the blood sugar levels after the glucose load more rapidly decreased in the colestimide group compared with the control group.
  • An FXR agonist, GW-4064 J. Med. Chem., vol. 43(16), pp.2971-2974, 2000 ), was orally administered in a dosage of 10 mg/kg for 4 days.
  • mice were dissected to isolate the livers.
  • the expression levels of the genes for cyp7 ⁇ , SHP and PEPCK in the livers were measured by quantitative PCR.
  • the primer sequences used for the real time quantitative PCR were the same as those mentioned in Example 1.
  • Guggulipid is a medicament widely used as a drug for treatment of hyperlipemia, and a product sold by Syntrax Innovations was used in the present invention.
  • the control group (HFD-cont) was fed with high fat diet (35.9% fat, UAR, Villemoison sur Orge, France), the guggulipid group (HFD-guggulipid) was fed with the high fat diet containing 2.5% guggulipid, and the colestimide group (HDF-colestimide) was fed with the high fat diet containing 2% colestimide.
  • high fat diet 35.9% fat, UAR, Villemoison sur Orge, France
  • the guggulipid group (HFD-guggulipid) was fed with the high fat diet containing 2.5% guggulipid
  • the colestimide group (HDF-colestimide) was fed with the high fat diet containing 2% colestimide.
  • insulin tolerance test was performed according to an ordinary method. Blood was collected before insulin load, then insulin was intraperitoneally administered, and blood sugar levels were measured 30, 60 and 90 minutes later.
  • oral glucose tolerance test was performed according to an ordinary method. Blood was collected before glucose load, then a glucose solution was orally administered, and blood sugar levels were measured 30, 60, 90 and 120 minutes later.
  • oxygen consumption was measured by using a basal metabolism measuring apparatus (Oxymax, Columbus Instruments).
  • the livers, white adipose tissues surrounding the epididymis and brown adipose tissues were isolated from the mice and weighed. Further, expression levels of genes for the liver bile acid synthetase, cyp7 ⁇ , the inhibitory nuclear receptor, SHP, and three proteins involved in thermogenesis in the brown adipose tissue (1. PPAR gamma coactivator 1a (PGC-1a), 2. uncoupler protein 1 (UCP-1), 3. deiodinase 2 (Dio2)) were measured by real time quantitative PCR.
  • PPC-1a PPAR gamma coactivator 1a
  • UCP-1 uncoupler protein 1
  • DIo2 deiodinase 2
  • SEQ ID NOS: 1 and 2 in the sequence listing for Cyp7 ⁇ , SEQ ID NOS: 3 and 4 in the sequence listing for SHP, SEQ ID NOS: 9 and 10 in the sequence listing for PGC-1a, SEQ ID NOS: 11 and 12 in the sequence listing for UCP-1, and SEQ ID NOS: 13 and 14 in the sequence listing for Dio2 were used.
  • Fig. 10 Changes in plasma glucose concentrations (mg/ml) after the insulin load in the control group ( ⁇ ), guggulipid group ( ⁇ ) and colestimide group ( ⁇ ) are shown in Fig. 10. As shown in Fig. 10, the blood sugar levels after the insulin load decreased in the guggulipid group and the colestimide group compared with those in the control group.
  • Fig. 11 Changes in plasma glucose concentrations (mg/ml) after the glucose load in the control group ( ⁇ ), guggulipid group ( ⁇ ) and colestimide group ( ⁇ ) are shown in Fig. 11. As shown in Fig. 11, the blood sugar levels after the glucose load rapidly decreased in the guggulipid group and the colestimide group compared with those in the control group.
  • the control group was fed with high fat diet (23.6% fat), and the colestimide group was fed with the high fat diet containing 2% colestimide.
  • glucose tolerance test was performed according to an ordinary method. The mice were fasted overnight, blood was collected before glucose load, then a glucose solution was orally administered at a dose of 1 g/kg body weight, and blood sugar levels were measured 30, 60, 90 and 120 minutes later. After 6 weeks of the administration, mice were dissected to isolate the livers. The expression levels of the genes for cyp7 ⁇ and SHP in the livers were measured by quantitative PCR.
  • the primer sequences used for the real time quantitative PCR were the same as those mentioned in Example 1.
  • the blood sugar levels more rapidly decreased after the glucose load in the colestimide group compared with those in the control group.
  • the control group was fed with high fat diet (23.6% fat), and the colesevelam hydrochloride group was fed with the high fat diet containing 2% colesevelam hydrochloride.
  • glucose tolerance test was performed according to an ordinary method. The mice were fasted overnight, blood was collected before glucose load, then a glucose solution was orally administered at a dose of 1 g/kg body weight, and blood sugar levels were measured 30, 60, 90 and 120 minutes later. After 6 weeks of the administration, mice were dissected to isolate the livers. The expression levels of the genes for cyp7 ⁇ and SHP in the liver were measured by quantitative PCR.
  • the primer sequences used for the real time quantitative PCR were the same as those mentioned in Example 1.
  • the blood sugar levels more rapidly decreased after the glucose load in the colesevelam hydrochloride group compared with those in the control group.
  • the control group was fed with high fat diet (23.6% fat), and the sevelamer hydrochloride group was fed with the high fat diet containing 2% sevelamer hydrochloride.
  • glucose tolerance test was performed according to an ordinary method. The mice were fasted overnight, blood was collected before glucose load, then a glucose solution was orally administered at a dose of 1 g/kg body weight, and blood sugar levels were measured 30, 60, 90 and 120 minutes later. After 6 weeks of the administration, mice were dissected to isolate the livers. Expression levels of the genes for cyp7 ⁇ and SHP in the livers were measured by quantitative PCR.
  • the primer sequences used for the real time quantitative PCR were the same as those mentioned in Example 1.
  • the blood sugar levels more rapidly decreased after the glucose load in the sevelamer hydrochloride group compared with those in the control group.
  • a novel agent for prophylactic and/or therapeutic treatment of diabetes can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05793213A 2004-10-15 2005-10-14 Mittel zur prävention und/oder behandlung von diabetes Withdrawn EP1810689A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004301027 2004-10-15
JP2005152124 2005-05-25
PCT/JP2005/018927 WO2006041150A1 (ja) 2004-10-15 2005-10-14 糖尿病の予防および／または治療薬

Publications (2)

Publication Number Publication Date
EP1810689A1 true EP1810689A1 (de) 2007-07-25
EP1810689A4 EP1810689A4 (de) 2009-07-22

Family

ID=36148436

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05793213A Withdrawn EP1810689A4 (de) 2004-10-15 2005-10-14 Mittel zur prävention und/oder behandlung von diabetes

Country Status (4)

Country Link
US (1) US20100055066A1 (de)
EP (1) EP1810689A4 (de)
JP (1) JPWO2006041150A1 (de)
WO (1) WO2006041150A1 (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465879A (en) * 2008-11-26 2010-06-09 Satiogen Pharmaceuticals Inc Apical sodium-dependent bile acid transporter (ASBT) inhibitors for reducing food intake and/or blood or plasma glucose levels
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
WO2014144650A2 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
EP2995317A1 (de) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
EP3266457A1 (de) 2011-10-28 2018-01-10 Lumena Pharmaceuticals LLC Gallensäurerückflusshemmer zur behandlung von cholestase-erkrankungen im kindesalter
EP4241840A2 (de) 2019-02-12 2023-09-13 Mirum Pharmaceuticals, Inc. Verfahren zur behandlung von cholestase

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030612A2 (en) * 2001-10-05 2003-04-17 City Of Hope Methods for modulating activity of the fxr nuclear receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
EP1210345B1 (de) * 1999-09-08 2004-03-03 Glaxo Group Limited Oxazol ppar antagonisten
US6777446B2 (en) * 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
US20020119958A1 (en) * 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
CA2454732C (en) * 2001-07-30 2010-07-20 Mitsubishi Pharma Corporation Drugs for ameliorating postcibal hyperglycemia
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US20040253327A1 (en) * 2003-06-12 2004-12-16 Niazi Sarfaraz K. Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides, and sugar and preventing or treating cardiovascular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030612A2 (en) * 2001-10-05 2003-04-17 City Of Hope Methods for modulating activity of the fxr nuclear receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006041150A1 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465879B (en) * 2008-11-26 2013-02-13 Satiogen Pharmaceuticals Inc Bile acid recylcing inhibitors for treatment of obesity and diabetes
GB2465879A (en) * 2008-11-26 2010-06-09 Satiogen Pharmaceuticals Inc Apical sodium-dependent bile acid transporter (ASBT) inhibitors for reducing food intake and/or blood or plasma glucose levels
EP2995317A1 (de) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
EP4137137A1 (de) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
EP3593802A2 (de) 2010-05-26 2020-01-15 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
US10512657B2 (en) 2011-10-28 2019-12-24 Lumena Pharmaceutials Llc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP3266457A1 (de) 2011-10-28 2018-01-10 Lumena Pharmaceuticals LLC Gallensäurerückflusshemmer zur behandlung von cholestase-erkrankungen im kindesalter
EP3278796A1 (de) 2011-10-28 2018-02-07 Lumena Pharmaceuticals LLC Gallensäurerückflusshemmer zur behandlung von hypercholämie und cholestatischer lebererkrankung
US11229661B2 (en) 2011-10-28 2022-01-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US11376251B2 (en) 2011-10-28 2022-07-05 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
WO2014144650A2 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
EP4241840A2 (de) 2019-02-12 2023-09-13 Mirum Pharmaceuticals, Inc. Verfahren zur behandlung von cholestase
EP4245367A2 (de) 2019-02-12 2023-09-20 Mirum Pharmaceuticals, Inc. Verfahren zur behandlung von cholestase
EP4424363A2 (de) 2019-02-12 2024-09-04 Mirum Pharmaceuticals, Inc. Verfahren zur wachstumssteigerung bei pädiatrischen patienten mit cholestatischer lebererkrankung

Also Published As

Publication number Publication date
EP1810689A4 (de) 2009-07-22
US20100055066A1 (en) 2010-03-04
WO2006041150A1 (ja) 2006-04-20
JPWO2006041150A1 (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
EP1810689A1 (de) Mittel zur prävention und/oder behandlung von diabetes
JP2018197252A (ja) 筋ジストロフィーを治療する方法
TW528597B (en) Medicament for preventive and/or therapeutic treatment of hyperphosphatemia
US20080293777A1 (en) Weight Loss Treatment
JP4353414B2 (ja) 食後過血糖改善剤
AU2017231832B2 (en) CXCR-2 inhibitors for treating crystal arthropathy disorders
EP1871365A2 (de) Verfahren zur behandlung von erkrankungen durch hemmung der funktion von molekularen chaperonen wie protein disulfid-isomerasen, diese enthaltende pharmazeutische zusammensetzungen und screening-verfahren zur identifizierung von therapeutischen mitteln
EP1039900B1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
EP2335709A1 (de) Agent for improving insulin resistance
RU2443417C2 (ru) Уменьшение избыточной массы тела или ожирения
WO2006000222A2 (en) The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
WO2022230920A1 (ja) 血中カルニチン増加剤
US6872751B2 (en) Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
US20220378866A1 (en) Combination therapy methods, compositions and kits
WO2001000187A2 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
JP2005047873A (ja) 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤及びそのための使用
KR101394594B1 (ko) 골 재흡수 및 골 형성 간의 불균형을 보정하는 방법 및 이를 위한 키트 및 조성물
KR20100017460A (ko) 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물
EP1757287A1 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von lipid-stoffwechselstörungen
WO2011000563A1 (en) Eltoprazine for the treatment of weight disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAKAI, KAORU,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: ISHII, SHINICHI,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: AUWERX, JOHAN,C/O UNIVERSITY LOUIS PASTEUR IGBMC

Inventor name: SUGIMOTO, KANAMI,MITSUBISHI PHARMA CORPORATION

Inventor name: WATANABE, MITSUHIRO,C/O UNIVERSITY LOUIS PASTEUR

Inventor name: SUZUKI, KAZUO,C/O ZOEGENE CORPORATION

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAKAI, KAORU,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: AUWERX, JOHAN,C/O UNIVERSITY LOUIS PASTEUR IGBMC

Inventor name: SUZUKI, KAZUO,C/O ZOEGENE CORPORATION

Inventor name: ISHII, SHINICHI,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: SUGIMOTO, KANAMI,MITSUBISHI PHARMA CORPORATION

Inventor name: WATANABE, MITSUHIRO

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI TANABE PHARMA CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WATANABE, MITSUHIRO

Inventor name: SAKAI, KAORU,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: ISHII, SHINICHI,C/O MITSUBISHI PHARMA CORPORATION

Inventor name: SUGIMOTO, KANAMI,MITSUBISHI PHARMA CORPORATION

Inventor name: AUWERX, JOHAN,C/O UNIVERSITY LOUIS PASTEUR IGBMC

Inventor name: SUZUKI, KAZUO,C/O ZOEGENE CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090622

17Q First examination report despatched

Effective date: 20090921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100406